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Description of platinum complexes
To obtain a platinum complex with sufficient hydrophobicity for encapsulation in POx NPs, we ultimately synthesized c,t,c-[Pt (NH 3 . The structures of the prodrugs were confirmed by spectroscopic analytical methods. Synthesis of cisplatin prodrug encapsulated nanoparticles requires that the prodrugs host be sufficiently soluble in organic solvents like methanol and acetonitrile. C 4 CP, C 6 CP, C 8 CP and C 10 CP dissolve in methanol (5 g/L, 5 g/L, 2 g/L and 2 g/L), making them suitable candidates for encapsulation.
The chemical structure of the hydrophobic Pt (IV) prodrugs that were prepared and the mechanism of release of cisplatin in the cells is shown below. R = (CH 2 ) n CH 3 , n = 2, 4, 6, 8 C4CP C6CP
C8CP C10CP 22.12, 25.46, 28.65, 28.72, 28.95, 28.96, 31.33, 35.70, 180.86; IR (KBr, 
Compiling all experimental data
Specifically, VE-822, ABT-263, AZD5363, AZD7762, AZD8055, cisplatin prodrugs (C10), (C8), (C6), (C4), and LDN-57444 can be solubilized under certain experimental conditions (i.e., feed ratio of polymer 10 mg/mL) at concentrations as high as at least about 2 mg/mL, with a LE of at least about 80% and a LC of at least about 10 %. Of these drugs, VE-822, ABT-263, AZD5363, and cisplatin prodrugs (C6) and (C4) showed very good ability for incorporation into POx micelles as they could be solubilized under the experimental conditions at concentrations as high as at least about 5 mg/mL, with a LE of at least about 80 % and LC of at least about 25 %. Furthermore, VE-822, ABT-263, and cisplatin prodrug (C6) showed exceptional ability for incorporation into POx micelles as they could be solubilized under the experimental conditions at concentrations as high as at least about 7 mg/mL, showing a LE of at least about 80% and a LC of at least about 40 %. Other drugs, such as KU55933, LY294002 and LY294002 HCl, olaparib, and sabutoclax had limited solubility; they could be solubilized at concentrations as high as at least about 1 mg/mL, with a LE of at least about 40 % and a LC of at least about 7 %.
For completeness, we included the data from previous reports for the third-generation taxoids including SB-T-1213, SB-T-121302, SB-T-121303, SB-T-1214, SB-T-121402, SB-T-1216, and SB-T-121602 (24), a vitamin D2 ergocalciferol, a third-generation retinoid bexarotene (55), a proteasome inhibitor bortezomib (BTZ), and the Hsp90 inhibitor 17-N-allylamino-17-demethoxygeldanamycin (17-AAG) (56) (see Data File S1). Our current results and previous reports (24, 32, 55, 56) showed that POx micelles can solubilize high amounts of paclitaxel (PTX) as well as other taxanes (e.g., docetaxel [DTX] and the third-generation taxoids) along with some other drugs such as ETO, 17-AAG, and BTZ. However, for many drugs, such as atazanavir (ATV), ATV sulfate, VE-821, bexarotene, ABT737, imiquimod, KU55933, LY2109761, LY294002 HCl, NVP-BEZ235, sabutoclax, wortmannin, and brefeldin, showed very low or negligible LC and LE values for all drug feed concentrations. The LC for these drugs was less than 10 % and, in most cases, less than 5 % or even 1 %. Along with the low LC, these drugs were characterized by low LE that were typically less than 26 % and, in several times, less than 10 % or even 1 %. The latter means that in these cases at least 75 % or even 99 % of valuable drugs are lost upon their formulation. 
